Show
Sort by
-
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
-
Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
-
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
-
Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps
-
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma
-
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
-
- Journal Article
- A1
- open access
EUFOREA consensus on biologics for CRSwNP with or without asthma
-
The GALEN rhinosinusitis cohort : chronic rhinosinusitis with nasal polyps affects health-related quality of life
-
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
-
Adherence to treatment in allergic rhinitis using mobile technology : the MASK study